Pfizer (PFE) Stock, Argus Research With A Buy Rating
b'The Pfizer (PFE) stock price is up about 32% year-to-date. Argus Research\'s David Toung says that they have a buy rating on the stock with a $55 price target. They see a stronger top-line growth over the next several years as investors are underestimating the sustainability of its Covid-19 vaccine franchise and its revenue contribution beyond 2021. Pfizer says that its Covid-19 pill cuts risk of hospitalization or death by 89%, and plans to submit its data to the FDA "as soon as possible."'